483 related articles for article (PubMed ID: 33211534)
1. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
[TBL] [Abstract][Full Text] [Related]
2. Access considerations for a COVID-19 vaccine for South Africa.
Bangalee V; Suleman F
S Afr Fam Pract (2004); 2020 Oct; 62(1):e1-e4. PubMed ID: 33179954
[TBL] [Abstract][Full Text] [Related]
3. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?
Towse A; Chalkidou K; Firth I; Kettler H; Silverman R
Value Health; 2021 May; 24(5):625-631. PubMed ID: 33933230
[TBL] [Abstract][Full Text] [Related]
4. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
So AD; Woo J
BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
[TBL] [Abstract][Full Text] [Related]
5. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccines pricing policy options for low-income and middle- income countries.
Guzman J; Hafner T; Maiga LA; Giedion U
BMJ Glob Health; 2021 Mar; 6(3):. PubMed ID: 33727281
[No Abstract] [Full Text] [Related]
7. The COVID-19 Innovation System.
Sampat BN; Shadlen KC
Health Aff (Millwood); 2021 Mar; 40(3):400-409. PubMed ID: 33539184
[TBL] [Abstract][Full Text] [Related]
8. The costs of coronavirus vaccines and their pricing.
Light DW; Lexchin J
J R Soc Med; 2021 Nov; 114(11):502-504. PubMed ID: 34732097
[No Abstract] [Full Text] [Related]
9. Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.
Painter C; Isaranuwatchai W; Prawjaeng J; Wee HL; Chua BWB; Huynh VA; Lou J; Goh FT; Luangasanatip N; Pan-Ngum W; Yi W; Clapham H; Teerawattananon Y
Appl Health Econ Health Policy; 2021 Jul; 19(4):463-472. PubMed ID: 34235643
[TBL] [Abstract][Full Text] [Related]
10. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
Robinson JC
Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
[TBL] [Abstract][Full Text] [Related]
12. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Critchley GJ; Zaric GS
Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
[TBL] [Abstract][Full Text] [Related]
13. [Pharmaceutical pricing; what is reasonable?].
Versteegh MM
Ned Tijdschr Geneeskd; 2020 Aug; 164():. PubMed ID: 32940991
[TBL] [Abstract][Full Text] [Related]
14. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
15. Market design to accelerate COVID-19 vaccine supply.
Castillo JC; Ahuja A; Athey S; Baker A; Budish E; Chipty T; Glennerster R; Kominers SD; Kremer M; Larson G; Lee J; Prendergast C; Snyder CM; Tabarrok A; Tan BJ; Więcek W
Science; 2021 Mar; 371(6534):1107-1109. PubMed ID: 33632897
[No Abstract] [Full Text] [Related]
16. A Call to Action Against Persistent Lack of Transparency in Vaccine Pricing Practices During the COVID-19 Pandemic.
Arguedas-Ramírez G
Ann Glob Health; 2022; 88(1):87. PubMed ID: 36311897
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?
Sarpatwari A; Pandya A; Hyle EP; Persad G
Ann Intern Med; 2022 Feb; 175(2):280-282. PubMed ID: 34748375
[TBL] [Abstract][Full Text] [Related]
18. Reference pricing with endogenous generic entry.
Brekke KR; Canta C; Straume OR
J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
[TBL] [Abstract][Full Text] [Related]
19. The COVID vaccine challenges that lie ahead.
Nature; 2020 Nov; 587(7835):522. PubMed ID: 33235368
[No Abstract] [Full Text] [Related]
20. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
Hu J; Mossialos E
Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
